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1. Introduction 
Several polypeptides have been claimed for thymic 
factors (hormones) which mediate the differentiation 
of T lymphocyte precursors to more matured T cells 
[ l]. Bach et al. [2] have obtained a circulating thymic 
factor from pig serum and shown its thymus origin. 
This factor has been reported to exhibit various 
immunological activities including @-conversion in 
vitro and in vivo [3], ind~lction of suppressor T cells 
in NZB mice [4], normalization of the abnormally 
high level of autologous erythrocyte-binding cells in 
ATx mice [S]. The chemical structure of this factor, 
designated Facteur Thymique Sdrique (FTS), was 
elucidated as a nonapeptide, <GIu-Ala-Lys-Ser- 
Gln-Gly-Gly-Ser-Asn-OH [6]. 
There exist few reports on the influence of the 
chemical structure of this factor on the biological 
activity [7,8]. Here, we describe the 8-conversion 
activity of synthetic FTS and its short chain analogs. 
The pentapeptide moiety (Lys-Ser-Gln-Gly-Gly) 
is shown to be a minimum essential part for the 
expression of full agonistic activity and the C-termi- 
nal part may have an enhancing role in the binding of 
this pentapeptide portion. 
2. Materials and methods 
Male C3H/He mice (6-9 weeks old) were used. 
Adult thymectomy was performed at 5-6 weeks. 
Azathiopurine (AZ) was purchased from Sigma 
Chemical Co. and used as the sodium salt. Anti-6 
Abb~eviutionsr FTS, serum thymic factor (Facteur Thymique 
Skique); 6, theta (Thy-l) antigen; ATx, adult thymectom- 
iced; AZ, azathiopurine; <Glu, L-pyroglutamic acid; Aac, 
acetoacetyl 
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serum (ABS, AKR anti-QH (Thy-l - 2) y-globulin) 
was obtained from Litton Bionetics. 
The peptides were synthesized by a conventional 
method (to be reported elsewhere) and are listed in 
table 1. The homogeneity of the peptide was ascer- 
tained by paper electrophoresis, thin-layer chroma- 
tography and high-performance liquid chromatog- 
raphy. 
2.1, Rosette ~n~i~iti~n assay 
The rosette technique and rosette inhibition pro- 
tocols in [9] were followed. Mice were used IO-30 
days after adult thymectomy for this assay. 
2.2. Cytotoxic assay 
Theta-negative pre-T cells in normal mouse spleen 
were enriched in A plus B layers by discontinuous 
bovine serum albumin gradient centrifugation [lo] 
and incubated with FTS peptide at 37°C for 2 h. 
The percentage of e-bearing cells was evaluated by a 
cytotoxicity test using At)S plus complement [ 1 I f. 
Dead cells were enumerated by a trypan blue dye 
exclusion test. 
3. Results and discussion 
The peptides were examined in vitro on the ability 
to convert the relatively AZ-resistant cells from ATx 
mouse spleen to @-positive rosette-form~g cells that 
are more susceptible to AZ [12]. Since all the active 
analogs are full agonists, the activity is expressed by 
the affinity, i.e., the half inhibitory concentration 
(hi-c.) defined as the concentration at which 50% of 
rosette-forming cells were inhibited by AZ (10 @g/ml) 
and the results are shown in table 1. (Des-<Glu’)-FTS 
is strongly active like FTS, with h.i.c. -IO-r2 M. This 
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Table 1 
Biological activity of FTS and the analogs 
Activity 
Abbreviation 
Rosette inhibitiona Cytotoxicb 
12 3 4 5 6 7 8 9 
<Glu-Ala-Lys-Ser-Gin-Gly-Gly-Ser-Asn-OH FTS 1.5 x lo-l2 1.5 x 10 -8' 
<Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-OH (des-As*')-FTS 1.3 x lo-l1 2.1 x 10 -7 
<Glu-Ala-Lys-Ser-Gln-Gly-Gly-OH (des-Ser 8 -ASP 9 )-FE 1.9 x lo-lo 1.3 x 10 -7 
<Glu-Ala-Lys-Ser-Gln-Gly-OH (des-Gly 7 -Asn 9 )-FE 3.0 x 10 -9 >lxlO -4 
<Glu-Ala-Lys-Ser-Gln-OH (des-Gly 6 -Asn 9 )-FE >lxlO -6 >lxlO -4 
<Glu-Ala-Lys-Ser-OH (des-Gin 5 -Asn 9 )-FTS >lxlO -6 >lxlO -4 
H-Ala-Lys-Ser-Gin-Gly-Gly-Ser-Asn-OH (des-<Glu 1 )-FTS 1.5 x lo-l2 1.5 x 10 -8 
H-Lys-Ser-Gln-Gly-Gly-Ser-Asn-OH (des-<Glu 12 -Ala )-FE 1.7 x 10 -10 2.1 x 10 -7 
H-Ser-Gln-Gly-Gly-Ser-Asn-OH 13 (des-<Glu -LYS ) -FTS >lxlO 
-6 
>lxlO 
-4 
Aac 
<Glu-Ala-LGs-Ser-Gln-Gly-Gly-Ser-Asn-OH & 3 (N -Aac-Lys )-FTS >lxlO 
-6 
>lxlO 
-4 
a Activity is shown in terms of the half inhibitory concentration (h.i.c.,see text for definition)ofpeptide 
b Activity is shown in terms of the peptide concentration giving a half-maximum response 
’ Maximum &conversion is obtained at 4.3 X 10e8 M 
indicates that the N-terminal pyroglutamyl residue is 
not necessary for the activity. The Lys3 residue is 
indispensable for the activity because the elimination 
of this residue gives a completely inactive peptide 
((des-<Glu’ -Lys3)-FTS). A similar observation was 
made with the same analog [7]. The acylation of 
e-amino group of Lys3 has also abolished the activity. 
Progressive removal of C-terminal 3 residues (Gly7, 
Se? and Asn’) decreases the affinity by factors of 
about 10 with each elimination. This is in contrast to 
[8], where complete disappearance of activity with 
the removal of Asn’ residue was shown. Much shorter 
peptides such as (des-Gly6-Asn’)-FTS are inactive at 
the doses tested (<10V6 M). 
B-conversion (Des-<Glu’-Ala*)-, (des-Asn’)- and 
(des-Se&Asn’)-FTS show -10% of FTS,activity, 
but in this assay system (des-Gly7-Asn’)-FTS which 
is a full agonist in the rosette inhibition assay (table 1) 
does not induce a significant B-conversion. The 
remainders of the analogs are inactive even at 1 O4 M. 
Inactive analogs lacking C-terminal few residues 
are shown to antagonize the action of FTS, whereas 
another inactive peptide devoid of Lys3 residue 
((des-<Glu’ -Lys3)-FTS) has no inhibitory property 
toward FTS even at 2 X lo-’ M (fig.1). The Lys3 resi- 
residue may be involved both in the exertion of the 
biological activity and in the binding of FTS to the 
receptor site on a target cell. 
The 0-conversion was also determined directly by As can be seen from table 1, the pentapeptide por- 
a cytotoxic assay [ 1 I]. Since all active analogs gave tion (Lys-Ser-Gln-Gly-Gly) is apparently a mini- 
the similar range of maximum response (14 * 2%), mum essential part of FTS molecule which bears the 
the activity is eyaluated by the concentration giving full e-inductive information. The C-terminal portion 
a half-maximum f3-conversion (table 1). The results (Se&Asn’) and also the Ala’ residue may act to 
are almost comparable with those in the rosette enhance the binding of rest part of the molecule. 
inhibition assay, though much higher peptide concen- Similar but more sophisticated example has been 
tration is required to detect the activity, reflecting documented in the case of ACTH [ 131. This view was 
the low sensitivity of cytotoxic assay with respect to further tested by two inactive analogs, one devoid 
109 
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Fig.1. Inhibition of FTS activity by short chain analogs. 
FTS (0.005 X 1O-9 M) was incubated together with either 
(de&m-Asrig)-FTS (-o-), (des-Gly6-Asn’)-FTS (-•-) 
or (des-<Glu’ -Lys3)-FTS (-A~) in the presence of AZ 
(10 fig/ml) and ATx mouse spleen cells. Dotted area corre- 
sponds to 2 SD of the control value without FTS. 
of C-terminal part and the other devoid of N-terminal 
few residues. When the mixture of (des-Gly6-Asn’)- 
FTS and (des-<Glu’-Lys3)-FTS were subjected to 
the rosette inhibition assay, a significant biological 
activity was restored as shown in fig.2. Simultaneous 
attack by two inactive peptides may compensate each 
other the Lys3 residue and C-terminal portion and 
they mimic the active conformation on a receptor site 
so that they could provide a O-inductive signal. The 
observed low affinity (fig.2) can be explained by the 
rare opportunity of correct hit by the two molecules. 
The circular dichroism measurements of FTS and the 
analogs indicate their structural flexibility in water 
(unpublished). FTS may have a particular conforma- 
tion on binding to the receptor site on a target cell. 
The results of this work agree most with a sychnolog- 
ical organization of O-inductive information for FTS 
rather than a case of rhenylogical organization [ 141. 
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Fig.2. Restoration of FTS like activity by two inactive short 
chain analogs. The mixture of indicated concentration of 
(de&lye -Asn9)-FTS and (des-<Glu’ -Lys3)-FTS was 
directly subjected to the rosette inhibition assay. Hatched 
area indicates 2 SD of the value with FTS (0.005 X 10m9 M). 
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